AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Linkedin X-twitter Vimeo

Helsinn Healthcare SA. All rights reserved. Helsinn Group 2025 ©

Exiting the US site

You are about to enter a website not intended for a US audience.
Please confirm your acceptance to continue

Continue
Cancel

Entering the US site

You are about to enter a website only intended for a US audience.
Please confirm your acceptance to continue.

Continue
Cancel

You are now leaving helsinn.com

Please click ‘Continue to external site’ if you want to continue.